Payment overview · 2025
General Payments
$1,012.76
50 reported records · 13 companies
Healthcare provider profile · identity verified
Terry Andrew Colotta, MD
Allopathic & Osteopathic Physicians|Family Medicine · MC KENZIE, TN · NPI 1659374296
Verified facts
What the public records show
CMS Open Payments records show Terry Andrew Colotta, MD received $1,012.76 in general payments during 2025 across 50 reported records.
ABBVIE INC. accounted for 28.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 549 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $284.02 | 28.0% | 21 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $257.36 | 25.4% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $144.37 | 14.3% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $96.99 | 9.6% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $51.62 | 5.1% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $27.37 | 2.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.42 | 2.6% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $26.41 | 2.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.06 | 2.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.48 | 2.1% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.73 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.80 | 1.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.13 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,012.76 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $244.36 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $230.88 | 17 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $144.37 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $96.99 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $78.04 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $53.14 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $53.14 | 4 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $27.37 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $26.41 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.00 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.00 | 5 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
86 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
90 | 90 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
549 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 800 | 103 |
| Furosemide | Furosemide | 753 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 729 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 701 | 101 |
| Potassium Chloride | Potassium Chloride | 621 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 620 | 71 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 559 | 111 |
| Eliquis | Apixaban | 549 | 44 |
| Gabapentin | Gabapentin | 506 | 95 |
| Tamsulosin Hcl | Tamsulosin Hcl | 499 | 57 |
| Lisinopril | Lisinopril | 493 | 85 |
| Divalproex Sodium | Divalproex Sodium | 420 | 30 |
| Trazodone Hcl | Trazodone Hcl | 378 | 51 |
| Ropinirole Hcl | Ropinirole Hcl | 372 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 357 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 354 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 350 | 37 |
| Carvedilol | Carvedilol | 317 | 43 |
| Losartan Potassium | Losartan Potassium | 306 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 303 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 300 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 53 |
| Risperidone | Risperidone | 272 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 267 | 14 |
| Mirtazapine | Mirtazapine | 263 | 25 |
| Sertraline Hcl | Sertraline Hcl | 254 | 29 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 251 | 34 |
| Omeprazole | Omeprazole | 245 | 66 |
| Pregabalin | Pregabalin | 243 | 42 |
| Buspirone Hcl | Buspirone Hcl | 239 | 35 |
| Metformin Hcl | Metformin Hcl | 235 | 53 |
| Doxepin Hcl | Doxepin Hcl | 223 | 22 |
| Prednisone | Prednisone | 221 | 63 |
| Dicyclomine Hcl | Dicyclomine Hcl | 210 | 24 |
| Simvastatin | Simvastatin | 210 | 39 |
| Montelukast Sodium | Montelukast Sodium | 206 | 47 |
| Alprazolam | Alprazolam | 204 | 35 |
| Allopurinol | Allopurinol | 203 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 194 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 188 | 27 |
| Famotidine | Famotidine | 183 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 174 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 173 | 33 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 169 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 164 | 23 |
| Meloxicam | Meloxicam | 160 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 155 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 151 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 147 | 43 |
| Spironolactone | Spironolactone | 145 | 17 |
| Baclofen | Baclofen | 144 | 17 |
| Levetiracetam | Levetiracetam | 142 | 12 |
| Tramadol Hcl | Tramadol Hcl | 136 | 26 |
| Glimepiride | Glimepiride | 134 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 132 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 129 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 129 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 127 | 21 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 120 | 80 |
| Lamotrigine | Lamotrigine | 119 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 119 | 22 |
| Promethazine Hcl | Promethazine Hcl | 118 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 116 | 20 |
| Memantine Hcl | Memantine Hcl | 114 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 112 | suppressed |
| Ozempic | Semaglutide | 111 | 15 |
| Ibuprofen | Ibuprofen | 106 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 103 | 12 |
| Lactulose | Lactulose | 101 | 24 |
| Lorazepam | Lorazepam | 101 | 15 |
| Olanzapine | Olanzapine | 100 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 99 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 99 | 20 |
| Divalproex Sodium Er | Divalproex Sodium | 96 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 93 | 22 |
| Benztropine Mesylate | Benztropine Mesylate | 92 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 92 | 11 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 90 | 90 |
| Jardiance | Empagliflozin | 89 | 12 |
| Cilostazol | Cilostazol | 88 | suppressed |
| Diazepam | Diazepam | 88 | 12 |
| Rivastigmine | Rivastigmine Tartrate | 87 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 86 | 12 |
| Celecoxib | Celecoxib | 85 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 84 | 16 |
| Cephalexin | Cephalexin | 83 | 57 |
| Clonazepam | Clonazepam | 83 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 82 | 47 |
| Xarelto | Rivaroxaban | 78 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 76 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 75 | 16 |
| Fenofibrate | Fenofibrate | 70 | suppressed |
| Finasteride | Finasteride | 69 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 28 |
| Amiodarone Hcl | Amiodarone Hcl | 65 | 16 |
| Lansoprazole | Lansoprazole | 65 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 13 |
| Oxcarbazepine | Oxcarbazepine | 60 | suppressed |
| Atenolol | Atenolol | 59 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | 14 |
| Meclizine Hcl | Meclizine Hcl | 59 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 16 |
| Primidone | Primidone | 58 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 57 | suppressed |
| Sucralfate | Sucralfate | 57 | 20 |
| Cimetidine | Cimetidine | 56 | suppressed |
| Ezetimibe | Ezetimibe | 56 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 55 | 12 |
| Cefdinir | Cefdinir | 55 | 46 |
| Januvia | Sitagliptin Phosphate | 54 | 15 |
| Linzess | Linaclotide | 54 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 52 | suppressed |
| Nystatin | Nystatin | 52 | 25 |
| Digoxin | Digoxin | 50 | suppressed |
| Fluconazole | Fluconazole | 50 | 30 |
| Propranolol Hcl | Propranolol Hcl | 49 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 47 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 46 | 12 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 46 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 42 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 42 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 41 | suppressed |
| Haloperidol | Haloperidol | 40 | suppressed |
| Methocarbamol | Methocarbamol | 40 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 39 | suppressed |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 37 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 13 |
| Azithromycin | Azithromycin | 35 | 18 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 35 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 35 | suppressed |
| Nitroglycerin | Nitroglycerin | 34 | 20 |
| Terbinafine Hcl | Terbinafine Hcl | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 18 |
| Albuterol Sulfate | Albuterol Sulfate | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Rivastigmine | Rivastigmine | 33 | suppressed |
| Carbamazepine | Carbamazepine | 31 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 23 |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 26 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 26 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 23 |
| Lovastatin | Lovastatin | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Xifaxan | Rifaximin | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 14 |
| Glipizide | Glipizide | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 12 |
| Valacyclovir | Valacyclovir Hcl | 18 | 11 |
| Ceftriaxone | Ceftriaxone Sodium | 17 | 12 |
| Clonidine | Clonidine | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 17 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 15 | 15 |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 11 |
| Novolog | Insulin Aspart | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lamotrigine Er | Lamotrigine | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Cyclosporine | Cyclosporine | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Quinine Sulfate | Quinine Sulfate | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Meperidine Hcl | Meperidine Hcl | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,012.76 · 50 records | ABBVIE INC. | BREZTRI, BRIXADI, CAPLYTA, Dexcom G6 Transmitter, EVENITY, FANAPT, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, REXULTI, SUBLOCADE, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, YUPELRI, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error